CASI Pharmaceuticals 2025 Q2 Earnings Wider Losses Despite Revenue Growth

CASI Pharmaceuticals reported its fiscal 2025 Q2 earnings on August 29, 2025, with revenue rising 4.9% year over year but a significant increase in per-share losses. The results fall short of demonstrating meaningful profitability, with no guidance adjustments provided by the company.

Revenue
The company’s total revenue for Q2 2025 reached $4.17 million, an increase of 4.9% compared to $3.98 million in the same period in 2024, indicating modest growth in its top-line performance.

Earnings/Net Income
Net losses widened significantly, with a net loss of $13.38 million in Q2 2025, up 92.0% from $6.96 million in the prior-year quarter. On a per-share basis, the loss expanded to $0.86 from $0.52, marking a 65.4% increase in the negative earnings per share. These continued losses underscore the company's ongoing financial challenges.

Price Action
The stock experienced mixed performance: a 5.71% decline in the latest trading day and a 2.12% drop for the week, followed by a strong 51.97% gain month-to-date as of August 29.

Post-Earnings Price Action Review
A backtested investment strategy of purchasing CASI 30 days after the earnings report has yielded poor results over the past three years. The strategy returned -42.29%, lagging far behind the benchmark’s 57.68% gain. The excess return was -99.97%, with a CAGR of -18.48%, reflecting significant underperformance. Notably, the strategy experienced a maximum drawdown of 0.00%, indicating no further decline but also no recovery from the initial loss.

CEO Commentary
David Cory, CEO, emphasized the company’s focus on its CID-103 program, including recent FDA clearance for the IND application in renal allograft antibody-mediated rejection and ongoing Phase 1/2 trials in chronic immune thrombocytopenic purpura. The company also executed a $20 million divestiture of its China-based assets to Kaixin Pharmaceuticals to concentrate on core development initiatives. Cory expressed confidence in CID-103’s potential and the company’s strategic direction.

Guidance
The company has not provided updated financial guidance in its latest earnings report.

Additional News
On April 11, 2025, CASI Pharmaceuticals was referenced in an article titled “CASI Pharmaceuticals (CASI)最新消息_今日CASI ...” with a placeholder message instructing readers to enable JavaScript and cookies. This is the only additional news noted within the required three-week period, with no further M&A activity, C-level changes, or dividend/buyback announcements reported.